Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723561 · ClinicalTrials.gov registry record · Phase 2
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
A Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06723561: Recruiting Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain, sponsored by Medical College of Wisconsin.
NCT06723561 is a Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 10 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06723561, a Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury. Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial. Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.
Primary Outcome
Generate initial data to calculate an effect size of LDN in the treatment of CNP in SCI. This will be utilized to plan a randomized control trial and submit for extramural funding.
Conditions Studied
Interventions
- DRUG 4.5mg daily dose of naltrexone
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06723561 shows while recruiting
NCT06723561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which 4.5mg daily dose of naltrexone is the first listed.
NCT06723561 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06723561 about?
NCT06723561 is a clinical study titled "Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury". The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spi...
What is the current status of trial NCT06723561?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06723561 study?
This clinical trial studies the following conditions: Spinal Cord Injury, Central Neuropathic Pain.
What interventions are being tested in trial NCT06723561?
The interventions under investigation include: 4.5mg daily dose of naltrexone (DRUG).
Who is sponsoring clinical trial NCT06723561?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723561 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06723561's enrollment target sits among peer trials
10 82nd of 99 higher than 8 of 99 other Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Electrical Control of Bladder in Spinal Cord Injury Patients
COMPLETED · Phase 2
-
Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
COMPLETED · Phase 2
-
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
COMPLETED · Phase 2
-
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01870752 · 10 participants · NA
Ovarian Tissue Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI